TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds.
Soleno Therapeutics Inc (SLNO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 40,532 | $3,395,771 | +10% | 1.45% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 250,000 | $5,000,000.00 | 3,074,542 | 2023-09-28 | Filing | |
| $21.00 | 36,939 | $775,719.00 | 2,824,542 | 2023-09-26 | Filing | |
| $20.03 | 117,996 | $2,363,459.88 | 2,787,603 | 2023-09-26 | Filing | |
| $19.11 | 88,685 | $1,694,770.35 | 2,669,607 | 2023-09-26 | Filing | |
| $18.24 | 52,691 | $961,083.84 | 2,580,922 | 2023-09-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.76 | 3,830 | $316,970.80 | 13,206 | 2025-07-01 | Filing | |
| $84.25 | 266 | $22,410.50 | 17,036 | 2025-06-24 | Filing | |
| $70.11 | 3,782 | $265,156.02 | 27,036 | 2025-04-01 | Filing | |
| $71.55 | 5,937 | $424,797.10 | 6,500 | 2025-03-28 | Filing | |
| $66.95 | 23,475 | $1,571,716.98 | 28,143 | 2025-03-27 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 250,441 | $20,981,947 | 0.03% | |
| 2. | 162 | $13,572 | 0% | |
| 3. | 48,498 | $4,063 | 0.17% | |
| 4. | 3 | $251 | 0% |
News See All
10 Unstoppable Stocks to Buy According to Hedge Funds
As per Morgan Stanley, investors can see gains in equities and high-quality fixed income for 2025, despite a slowdown in global economic growth. In the Midyear Investment Outlook, Morgan Stanley Research...
FDA Approval for its Drug Lifted Soleno Therapeutics (SLNO) Shares by 60%
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2025 investor letter.
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an ‘Overweight’ rating on the stock with a $145 price target.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
Soleno Therapeutics, Inc.
11 Best Performing Healthcare Stocks to Buy Now
On April 15, CNBC reported that President Trump's healthcare-focused executive order brought in a win for the sector.
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q1 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Soleno Therapeutics First Quarter 2025 Earnings Conference Call. At this time, note that all participants are in a listen-only mode.
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential
On December 30, MJP Wealth Advisors chief investment officer Brian Vendig appeared on Yahoo! Finance's Catalysts to discuss the potential outlook of small cap stocks in 2025.
10 Biggest Stocks with Negative Beta to Consider
Beta is a measurement of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and down compared to other stocks.
Billionaire Hedge Funds
